Thermo Fisher Scientific Inc. $TMO Stock Sold by Rockland Trust Co.

Key Points

• Rockland Trust cut its Thermo Fisher Scientific stake by 46.3% in the third quarter, selling 29,916 shares and retaining 34,723 shares worth approximately $23.4 million. Institutional investors collectively own 89.23% of the company.
• Thermo Fisher reported quarterly revenue of $11.99 billion and EPS of $6.03, exceeding analyst expectations, while revenue rose 10.5% year over year. The company reaffirmed fiscal 2026 EPS guidance of $24.93 to $25.33.
• TMO shares traded near $666.97, close to their 52-week high, and analysts maintained a consensus “Moderate Buy” rating with a $628.78 target price. The company also declared a quarterly dividend of $0.47 per share, yielding 0.3% annually.

Rockland Trust Co. decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 46.3% during the third quarter, according to its most recent filing with the SEC. The firm owned 34,723 shares of the medical research company's stock after selling 29,916 shares during the period. Rockland Trust Co.'s holdings in Thermo Fisher Scientific were worth $23,440,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Legacy Wealth Managment LLC ID raised its stake in Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock worth $25,000 after buying an additional 22 shares in the last quarter. Kilter Group LLC bought a new stake in Thermo Fisher Scientific during the 2nd quarter valued at $25,000. Allied Private Wealth LLC purchased a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at $26,000. MBM Wealth Consultants LLC purchased a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth $29,000. Finally, Pingora Partners LLC bought a new stake in Thermo Fisher Scientific during the second quarter valued at about $30,000. 89.23% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CAO Joseph Holmes sold 420 shares of the firm's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at $1,734,546.46. This trade represents a 12.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the completion of the sale, the chief operating officer owned 24,651 shares in the company, valued at approximately $13,927,815. This represents a 1.60% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 73,768 shares of company stock valued at $44,122,820. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Performance

TMO stock traded up $12.17 during trading on Monday, reaching $666.97. The company had a trading volume of 640,221 shares, compared to its average volume of 2,243,463. The company has a market cap of $246.61 billion, a price-to-earnings ratio of 35.87, a price-to-earnings-growth ratio of 2.74 and a beta of 0.87. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $683.63. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The firm has a 50-day simple moving average of $618.62 and a 200-day simple moving average of $535.16.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion during the quarter, compared to analysts' expectations of $11.71 billion. During the same quarter last year, the company posted $4.28 earnings per share. The business's quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific's payout ratio is currently 10.11%.

Analysts Set New Price Targets

A number of equities analysts have commented on TMO shares. Citigroup downgraded shares of Thermo Fisher Scientific from a "buy" rating to an "underperform" rating in a report on Wednesday, September 9th. CLSA started coverage on shares of Thermo Fisher Scientific in a research report on Thursday, September 3rd. They issued an "outperform" rating and a C$748.00 price objective on the stock. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and set a $720.00 price objective on shares of Thermo Fisher Scientific in a research note on Friday, September 25th. Weiss Ratings upgraded shares of Thermo Fisher Scientific from a "hold (c)" rating to a "hold (c+)" rating in a research note on Friday, August 28th. Finally, HSBC raised Thermo Fisher Scientific from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, September 1st. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific has an average rating of "Moderate Buy" and a consensus target price of $628.78.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company's portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.